Beyond the Hype: Why Global Expansion in MedTech Still Hinges on Old-School Training

The headline sounds straightforward enough: a medical device company, Baird Medical, has announced its first microwave ablation procedures in Vietnam and Argentina. On the surface, it’s a routine business expansion update. But the real story isn’t about the technology itself—it’s about the immense, often overlooked challenge of translating a sophisticated tool from a controlled environment into the messy, variable reality of global healthcare systems. Getting the device into the operating room is the easy part. The hard work begins with the hands that hold it.

Microwave ablation is a powerful technique. It uses electromagnetic energy to generate heat and destroy diseased tissue, often for tumors in organs like the liver, kidney, or lung. It’s a less invasive alternative to surgery, promising shorter recovery times and potentially fewer complications. Companies like Baird have spent years refining the hardware and the software algorithms that control the energy delivery. Yet, a device is only as good as the clinician wielding it. The successful rollout in these new markets will depend less on the engineering specs and more on a far less glamorous asset: robust, hands-on training infrastructure.

The Training Chasm

Consider the difference between a pilot flying a simulator and navigating a real storm over the ocean. The simulator is perfect; the storm is chaotic. The same chasm exists in procedural medicine. A new ablation device might come with pristine manuals and simulated training modules. But the reality of a procedure involves navigating a patient’s unique anatomy, adjusting for unexpected bleeding, and making split-second decisions based on real-time imaging feedback that never looks as clean as the textbook diagrams.

For a company like Baird, establishing a foothold in Vietnam and Argentina isn’t just about selling machines. It requires building a sustainable ecosystem of expertise. This means:

• Identifying and cultivating local champions: Finding the early-adopter surgeons and radiologists who are not only skilled but also willing to become mentors for their peers.
• Adapting training to local constraints: Can the training be done effectively with the available imaging equipment? Are there sufficient cadaver or animal labs for practice, or must the company rely more heavily on proctored live cases?
• Navigating regulatory and institutional culture: Gaining approval to run a hands-on workshop is one thing. Getting hospital administrators to free up their busy specialists for days of off-site training is another battle entirely.

This is where many medtech expansions stumble. The focus is on the product launch event, not the multi-year journey of building competency. A device that sits underutilized because the local staff isn’t confident or capable enough to use it for complex cases is a failed investment, regardless of its technical brilliance.

Lessons from the Software World

There’s a useful parallel in the software industry. The best SaaS (Software-as-a-Service) companies know that selling the subscription is just the beginning. Their real competitive advantage lies in their onboarding process, their customer success managers, and their vast libraries of tutorials and community forums. They understand that value is only realized through adoption, and adoption requires support.

MedTech could learn from this. The most forward-thinking device companies are moving beyond the one-and-done training model. They’re investing in ongoing proctoring programs, where an expert remains virtually or physically on-call for a new clinician’s first dozen independent procedures. They’re creating digital platforms for surgeons to share anonymized case studies and technique tips, fostering a community of practice that outlives any single sales representative’s visit. The technology transfer is merely the spark; the long-term growth is fueled by shared knowledge.

Baird’s announcement is a positive step, signaling that advanced interventional tools are becoming more globally accessible. However, the true measure of its success in these new markets won’t be found in the initial sales figures. It will be seen two or three years from now, in the consistency of outcomes, in the number of clinicians confidently performing complex ablations independently, and in whether the technology has become a reliable part of the standard of care. That victory is won not in a boardroom, but in the methodical, painstaking work of education.

Source: original report